The VCU Massey Comprehensive Cancer Center has introduced bioimpedance spectroscopy, a cutting-edge technology that can detect lymphedema before symptoms appear, giving clinicians a critical tool for early intervention. The device has been incorporated into routine patient check-ins alongside standard vital signs, making fluid monitoring seamless and efficient.
Lymphedema, a condition that causes swelling in the limbs, often develops in breast cancer patients following lymph node removal or radiation. Early detection is key to preventing discomfort and complications. With bioimpedance spectroscopy, clinicians can quickly measure fluid levels in a patient’s arms and legs, allowing for timely management and treatment.
The process is simple and noninvasive. Patients place their bare hands and feet on the device, and in less than two minutes, the machine provides detailed results on fluid accumulation in specific limbs. Prior to surgery, baseline measurements are recorded so clinicians can track changes over time and identify early signs of lymphedema.
“The results are automatically uploaded to a patient’s electronic medical records, and clinicians are alerted if there are any significant changes,” said Kandance P. McGuire, MD, FACS, interim senior vice president of the Cancer Service Line and chief of breast surgery at VCU Massey Comprehensive Cancer Center. “This allows us to make timely referrals to rehabilitation services when necessary, ensuring patients receive the care they need before symptoms worsen.”
Dr. McGuire explained that bioimpedance spectroscopy works by measuring how tissue resists a small electrical signal. “The device tracks how quickly the signal travels from the hands to the feet,” she said. “The slower the signal, the more fluid is present in the tissue, which can indicate the early stages of lymphedema.”
Modern bioimpedance devices resemble body composition scales, making them easy for patients to use and quick for clinicians to analyze. Unlike older methods that relied on cumbersome EKG leads, the new technology allows for rapid, accurate, and noninvasive assessments, potentially transforming post-surgical care for breast cancer patients and improving long-term outcomes.
